脳脊髄炎(Encephalomyelitis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Encephalomyelitis Overview 6
Therapeutics Development 7
Pipeline Products for Encephalomyelitis – Overview 7
Pipeline Products for Encephalomyelitis – Comparative Analysis 8
Encephalomyelitis – Therapeutics under Development by Companies 9
Encephalomyelitis – Therapeutics under Investigation by Universities/Institutes 10
Encephalomyelitis – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Encephalomyelitis – Products under Development by Companies 13
Encephalomyelitis – Products under Investigation by Universities/Institutes 14
Encephalomyelitis – Companies Involved in Therapeutics Development 15
Effimune SAS 15
Endocyte, Inc. 16
Immune Technologies and Medicine 17
InteKrin Therapeutics, Inc. 18
Io Therapeutics, Inc. 19
Merck & Co., Inc. 20
Momenta Pharmaceuticals, Inc. 21
Encephalomyelitis – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
Anatabine – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Antibody for Autoimmune Disorders and Inflammation – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EC-1496 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FR-104 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
INT-131 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IRX-5183 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Peptides for Central Nervous System and Musculoskeletal Disorders – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PETIR-001 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PSA-20 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SCH-546738 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
thymulin – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Encephalomyelitis – Recent Pipeline Updates 44
Encephalomyelitis – Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48